The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
Florida judge sentences reinsurance manager to 10 months’ time served for role in Ecuadorian bribery scheme
July 2, 2025
News Alert
New Post
Rising Cross-Border Enforcement Risk for Companies Operating in Latin America
June 26, 2025
Insight